Drug Shortage Report for OZEMPIC
| Report ID | 202216 |
| Drug Identification Number | 02471469 |
| Brand name | OZEMPIC |
| Common or Proper name | Ozempic |
| Company Name | NOVO NORDISK CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | SEMAGLUTIDE |
| Strength(s) | 1MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | 1 |
| ATC code | A10BJ |
| ATC description | |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2023-08-21 |
| Actual start date | |
| Estimated end date | 2024-03-31 |
| Actual end date | 2024-01-17 |
| Shortage status | Resolved |
| Updated date | 2024-04-05 |
| Company comments | Due to the combination of overall global supply constraints coupled with increased demand, Novo Nordisk Canada Inc. is experiencing continued temporary delays on the shipments and delivery of Ozempic®. While we continue to manufacture and ship Ozempic®, patients may experience delays. We are working hard to address this issue and taking all relevant actions to ensure a continuous supply of medicine to Canadian patients. We will continue to monitor wholesale orders for extreme exceptions above normal demand, ensuring equal access for our patients |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 101-2476 ARGENTIA ROAD MISSISSAUGA, ONTARIO CANADA L5N 6M1 |
| Company contact information | 1 800 465 4334 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2023-08-17 | French | Compare |
| v1 | 2023-08-17 | English | Compare |